Liminal BioSciences

Liminal BioSciences is focused on discovering and developing novel small molecule therapeutics that modulate G protein-coupled receptor pathways (GPCRs).

Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of novel distinctive small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company is developing new proprietary small molecule therapeutic candidates with the intention of developing best-in-class therapeutics for the treatment of unmet metabolic, inflammatory and fibrotic diseases, using its integrated drug discovery platform, expertise in medicinal chemistry and deep understanding of GPCR biology. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK.

• Small molecules
• Immunology/inflammation
• Gastrointestinal Tract
• Diabetes
• Allergic Disorders
• Dermatology
• Metabolic Disorders